EU/UK QPPV and heads the QPPV Office at Novavax
Dr. Julia Appelskog is a leading pharmacovigilance (PV) expert with over 22 years of experience in drug safety, clinical operations, and quality assurance. She serves as the EU/UK QPPV and heads the QPPV Office at Novavax. Dr. Appelskog has been instrumental in integrating AI into PV practices, driving innovation across the pharmaceutical industry. Her background includes eight years of extensive research in cancer and diabetes, with a PhD from the Karolinska Institute. She has led global PV teams at large pharma and has held leadership roles in various industry associations. Dr. Appelskog is also the author of “ChatGPT in Pharmacovigilance” and “AI Text Tools for Everyone,” exploring AI’s impact on drug safety and daily life.